Retrospective comparison between antiglobulin enhanced-complement dependent cytotoxicity crossmatches and flow cytometric crossmatches in patients with preformed HLA antibodies

1995 ◽  
Vol 44 ◽  
pp. 114
2011 ◽  
Vol 72 ◽  
pp. S19
Author(s):  
Patricia Keiko Saito ◽  
Roger Haruki Yamakawa ◽  
Luciene Christina Marques Pereira da Silva ◽  
Waldir Veríssimo da Silva ◽  
Sueli Donizete Borelli

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4706-4706
Author(s):  
Won Ho Choe ◽  
Seongsoo Jang ◽  
Hyun-Sook Chi ◽  
Chan-Jeoung Park ◽  
Ho Joon Im

Abstract Abstract 4706 Background: Determining the chimerism in stem cell transplantation (SCT) is important in the monitoring of engraftment. Conventional monitoring methods such as short tandem repeat (STR) PCR are labor intensive and difficult in showing the changes of cell subpopulations. Nowadays, HLA-haploidentical SCT is performed actively and flow cytometric analysis using anti HLA antibody targeted for the different HLA between donor and recipient in HLA-haploidentical SCT can be useful by observing changes of cell subpopulations and determining the chimerism. Methods: Based on the study of HLA distribution in Korean population, we designed the panel of HLA monoclonal antibody that can detect and differentiate major HLA of Korean population. This panel was verified against 23 cases of HLA-haploidentical SCT. Flow cytometric analysis was performed using anti-HLA-antibodies on one pediatric patient with aplastic anemia who underwent HLA-haploidentical SCT. Tests were performed every day since SCT. The appearance or disappearance of donor and/or recipient HLA was observed using antibodies against mismatched HLA. Donor and/or recipient T cells, B cells, NK cells, and monocytes were observed using CD3, CD19, CD56, and CD13 respectively. The flow cytometric results were interpreted by observing the changes in subpopulations of detected cells and determining the engraftment status of patients. Results: A total of 11 anti-HLA-A-antibodies and anti-HLA-B-antibodies were selected. They cover 97.9% of HLA-A and 8.6% of HLA-B in Korean population. In the verification of our panel of HLA monoclonal antibody, we distinguished donor and recipient cells in 21 of 23 HLA-haploidentical SCT cases. In our case, the patient had HLA-A2/A24 while the donor had HLA-A2/A33. Recipient type of CD3(+) and HLA-A33(-) T cells appeared in first few days but donor type CD3(+) and HLA-A33(+) T cells appeared at day 20 and were increased. Donor type CD56(+) and HLA-A33(+) cells were seen at analysis done in day 8 and continued to appear. HLA-A33(+) cells were consistently observed and increased throughout the follow up period, showing the process of engraftment of donor stem cells. Conclusion: We were able to apply our flow cytometric analysis design using HLA monoclonal antibody for the detection of chimerism in HLA-haploidentical SCT. This method was more simple and sensitive than conventional monitoring techniques. Moreover, this method allowed us to observe the dynamics of changes in cell subpopulations after HLA-haploidentical SCT. Flow cytometric analysis can be considered as a strong tool for observing the changes in cell subpopulations and the monitoring the engraftment of HLA-haploidentical SCT. Disclosures: No relevant conflicts of interest to declare.


2007 ◽  
Vol 88 (5) ◽  
pp. 1415-1422 ◽  
Author(s):  
Masaya Takemoto ◽  
Koichi Yamanishi ◽  
Yasuko Mori

CD46 (membrane cofactor protein; MCP) is a molecule that functions as either a complement-regulatory protein (CRP) or a receptor for some pathogens, including human herpesvirus 6. DNA microarray analysis suggested that the expression of CD46 was upregulated in T cells infected with human herpesvirus 7 (HHV-7). Northen and Western blot analyses supported this result at both the transcriptional and translational levels. Flow-cytometric analysis revealed that upregulation of CD46 occurred at a late stage of infection in both SupT1 cells and primary CD4+ T cells, and also that expression of another CRP, CD59, was increased at a late stage of infection. Whether these CRPs actually function in HHV-7-infected cells was addressed and it was found that HHV-7-infected cells were more resistant to complement-dependent cytotoxicity than were uninfected cells. This study is the first report demonstrating that HHV-7 infection causes elevation of the CRPs CD46 and CD59, which may be a possible mechanism for HHV-7 to evade humoral immunity via complement.


2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Gerald Schlaf ◽  
Susanne Apel ◽  
Anja Wahle ◽  
Wolfgang W. Altermann

In order to select recipients without donor-specific anti-HLA antibodies, the complement-dependent cytotoxicity crossmatch (CDC-CM) was established as the standard procedure about 40 years ago. However, the interpretability of this functional assay strongly depends on the vitality of isolated donors’ lymphocytes. Since the application of therapeutic antibodies for the immunosuppressive regimen falsifies the outcome of the CDC-crossmatch as a result of these antibodies’ complement-activating capacity in the recipients’ sera, we looked for an alternative methodical approach. We here present 27 examples of AB0 blood group-incompatible living kidney allograft recipients who, due to their treatment with the humanized chimeric monoclonal anti-CD20 antibody Rituximab, did not present valid outcomes of CDC-based pretransplant cross-matching. Additionally, four cases of posttransplant cross-matching after living kidney allografting and consequent treatment with the therapeutic anti-CD25 antibody Basiliximab (Simulect) due to acute biopsy-proven rejection episodes are presented and compared regarding CDC- and ELISA-based crossmatch outcomes. In all cases, it became evident that the classical CDC-based crossmatch was completely unfeasible for the detection of donor-specific anti-HLA antibodies, whereas ELISA-based cross-matching not requiring vital cells was not artificially affected. We conclude that ELISA-based cross-matching is a valuable tool to methodically circumvent false positive CDC-based crossmatch results in the presence of therapeutically applied antibodies.


2018 ◽  
Vol 64 (1) ◽  
pp. 43-49
Author(s):  
Natsumi Nishimoto ◽  
Takayuki Maruhashi ◽  
Kanae Iwahara ◽  
Reina Ishikawa ◽  
Kozue Susa ◽  
...  

1999 ◽  
Vol 60 (12) ◽  
pp. 1293-1302 ◽  
Author(s):  
Rui Pei ◽  
Jar-how Lee ◽  
Terrence Chen ◽  
Susan Rojo ◽  
Paul I. Terasaki

Author(s):  
Sujata Gaitonde ◽  
Mohamed Hassan ◽  
Vikas Mehta ◽  
Enrico Benedetti ◽  
Ivo Tzvetanov ◽  
...  

Abstract Objectives To describe the histopathologic and immunophenotypic features of a temporary splenic allograft exposed to massive donor-specific antibody (DSA) insult. Methods A human cadaveric donor splenic allograft was temporarily transplanted in a highly sensitized patient with the intention of removing DSA before intestinal transplantation from the same donor. Before splenic transplant, the patient had several preformed cytotoxic DSAs that resulted in positive flow cytometric and complement-dependent cytotoxicity crossmatch. The splenic allograft was removed before intestinal transplantation and evaluated by H&E and immunohistochemical stains. Results Explanted donor splenic allograft showed several histopathologic changes: expanded red pulp secondary to congestion and marked neutrophilic and macrophage infiltration in the sinusoids, numerous neutrophilic microabscesses, and focal capillaritis. The C4d and IgG immunohistochemical stains were diffusely positive in the endothelial lining of the capillaries and sinusoidal lining, indicating diffuse IgG deposition and complement activation. Conclusions We propose that the noted changes are features of splenic acute antibody-mediated rejection (AMR). Additional cases are required to determine all the features of splenic AMR. To our knowledge, this is the first report of histopathologic changes in donor spleen after exposure to DSA for a short duration.


2016 ◽  
Vol 129 (1-2) ◽  
pp. 33-37 ◽  
Author(s):  
Nataša Katalinić ◽  
Marina Fućak ◽  
Tajana Crnić ◽  
Milena Ćurković ◽  
Alma Starčević ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document